| Autor: |
Kim C; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA., Bhatta S; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA., Cyprien L; DOCS Global, North Wales, PA 19454, USA., Fonseca R; Mayo Clinic, 5777 East Mayo Boulevard, Phoenix, AZ 85064, USA., Hernandez RK; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of bone oncology [J Bone Oncol] 2018 Dec 26; Vol. 14, pp. 100215. Date of Electronic Publication: 2018 Dec 26 (Print Publication: 2019). |
| DOI: |
10.1016/j.jbo.2018.100215 |
| Abstrakt: |
Skeletal-related events (SREs) are common bone complications in multiple myeloma (MM). However, there are few real-world reports of their incidence. In this study, a database of oncology electronic health records was linked to administrative claims data. Patients identified were aged ≥18 years and newly diagnosed with MM, had ≥1 clinic visit within 1 month of diagnosis, and ≥1 year of follow-up after diagnosis. The study period was January 1, 2011 to December 31, 2016. 343 patients were included, 35% of whom had a baseline history of any SRE. During a median follow-up of 25.7 months, 34% of patients experienced SREs after diagnosis. Median time to SRE was 167 days. Among patients experiencing an SRE, 68% had an SRE within the first year. The incidence rate of SREs at 1 year following MM diagnosis for patients with baseline history was 103/100 person-years (PY) versus 16/100PY for patients without baseline history. SRE incidence rates within 3 months of initiating a line of therapy increased with subsequent lines (line 1: 81/100PY, line 2: 118/100PY, line 3: 150/100PY). Risk of SREs was similar across different anti-MM regimens, including proteasome inhibitor-based regimens. These results highlight the importance of continued surveillance and management of MM-associated bone disease. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
